

Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-42 (canceled)

43. (previously presented) A pharmaceutical composition comprising ritonavir, wherein ritonavir in said composition is formulated as a solid dispersion of amorphous ritonavir in a matrix including a water soluble polymer.

44. (previously presented) A pharmaceutical composition of claim 43, comprising a gelatin capsule which encapsulates said solid dispersion.

45. (previously presented) A pharmaceutical composition of claim 43 which is a tablet comprising said solid dispersion.

46. (previously presented) The pharmaceutical composition of claim 43, wherein said water soluble polymer is PEG.

47. (previously presented) The pharmaceutical composition of claim 43, wherein said water soluble polymer is PEG 8000.

48. (currently amended) The pharmaceutical composition of claim 43, wherein said solid dispersion further comprises (2S,3S,5S)-2-(2,6-dimethylphenoxyacetyl)amino-3-hydroxy-5-[2S-(1-tetrahydro-pyrimidin-2-onyl)-3-methylbutanoyl]amino-1,6-diphenylhexane (ABT-378).

49. (previously presented) The pharmaceutical composition of claim 43, further comprising a pharmaceutically-acceptable filler, diluent, lubricant or disintegrant.

50. (previously presented) The pharmaceutical composition of claim 43, wherein said solid dispersion is ground and formulated into a delivery system.

51. (previously presented) A method of treating an HIV infection comprising administering a pharmaceutical composition of claim 43 to a mammal in need of such treatment.

52. (currently amended) A method of treating an HIV infection comprising administering the **[[a]]** pharmaceutical composition of claim 48 to a mammal in need of such treatment.